Aims & Scope:

Artificial Intelligence in Medicine: Disease diagnosis, drug development and treatment personalization is a special issue of the journal Current Medicinal Chemistry. It publishes review articles from a wide variety of interdisciplinary perspectives concerning the theory and practice of artificial intelligence in medicine, especially about disease diagnosis, drug development and precision medicine.

Artificial intelligence in medicine may be defined as the scientific discipline pertaining to research studies, projects, and applications that aim to support decision-based medical tasks through knowledge- and/or data-intensive computer-based solutions that ultimately support and improve the performance of a human health-care provider.

Submitted review must refer to the real-world medical and pharmaceutical domains, considered and discussed at the proper depth, from both the technical and the medical points of view. The inclusion of a clinical assessment of the usefulness and potential impact of the submitted work is strongly recommended.

English exposition must also be clear and revised with care. Authors are kindly requested to revise their manuscripts with the help of co-authors that are fluent in English or language editing services before submitting their contribution. Papers written in poor English are likely to be rejected.

Keywords: Artificial Intelligence in Medicine; Machine Learning; Biomarker discovery; Drug development; Treatment personalization; Metabolomics; Proteomics; Genomics

Subtopics to be covered (main bioactive component):

- Biomarker for disease diagnosis or prognosis
- Omics tool for biomarker discovery or drug design
- Metabolomics, proteomics, miRNomeics, fluxomic and other omics tools in biomarker discovery and treatment response prediction
- Artificial intelligence for biomarker discovery and drug design
- Artificial intelligence in Personalized medicine

Schedule:
-Thematic issue submission deadline: October 2020